Antenatal magnesium sulphate reduces cerebral palsy after preterm birth, implementation into clinical practice needs to be accelerated globally to benefit preterm babies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. International disparities in use of antenatal magnesium sulfate and antenatal steroids for the preterm baby.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
   Review
2. Antenatal magnesium sulphate for preterm foetal neuroprotection in low- and middle-income countries: a scoping review of research studies and guidelines.Journal of global health · 2026
   Article
3. Demonstrating the value for money of implementing evidence-based treatment: the case for further investment in magnesium sulphate as a neuroprotectant for preterm births.Frontiers in health services · 2025
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as